| Bioactivity | ADPM06, a lead candidate azadipyrromethene, is a novel nonporphyrin photodynamic therapeutic (PDT) agent. ADPM06 exhibits IC50 values in the micro-molar range in human tumor cells and induces apoptosis[1]. |
| Invitro | The efficacy of ADPM01 is completely ablated at a 1% oxygen level in Hela and MRC5 cell lines. ADPM06 displays only a partial reduction in light-induced activity in hypoxic as compared to normoxic conditions[1].ADPM06-PDT induces ER stress and unfolded protein response[2].ADPM06-PDT induces apoptosis and involves caspase enzymatic activity[2].Following ADPM06-PDT, a rapid processing of XBP1 mRNA occurs resulting in the removal of an intron from the mRNA in a spliceosome-independent manner, a post-transcriptional modification catalyzed by the action of activated inositol-requiring protein 1 (IRE1)[2].ADPM06-PDT-induced apoptosis involves the generation of ROS[2]. Cell Viability Assay[1] Cell Line: |
| Name | ADPM06 |
| CAS | 490035-90-0 |
| Formula | C34H24BBr2F2N3O2 |
| Molar Mass | 715.19 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
ADPM06
CAS: 490035-90-0 F: C34H24BBr2F2N3O2 W: 715.19
ADPM06, a lead candidate azadipyrromethene, is a novel nonporphyrin photodynamic therapeutic (PDT) agent. ADPM06 exhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.